Although the majority of primary breast cancers are ER-positive (ER+) and respond well to antiestrogen therapy, up to one-third of patients with breast cancer lack ER (ER−) at the time of diagnosis, and a fraction of breast cancers that are initially ER+ lose ER expression during tumor progression [2]. This evidence concerns the gene ESR1 and breast carcinoma.